J Clin Lipidol. 2026 Jul 20:S1933-2874(26)00455-1. doi: 10.1016/j.jacl.2026.07.025. Online ahead of print.
ABSTRACT
BACKGROUND: Inclisiran is a small interfering RNA that safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing (after the initial and 3-month doses). However, data on real-world inclisiran use are limited.
OBJECTIVE: This descriptive, noninterventional, retrospective chart review aimed to assess dosing schedule adherence, patient profiles, and LDL-C change in participants prescribed inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in routine clinical practice in Austria.
METHODS: Participants with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent, or familial hypercholesterolemia, LDL-C ≥70 mg/dL <6 months before the 1st inclisiran dose who received ≥1 inclisiran dose between February 1, 2021, and June 30, 2022, were included.
RESULTS: Of participants who initiated inclisiran (N = 95), 96.8% and 89.5% received the 2nd and 3rd doses, respectively, with 95.5% receiving the 2nd dose <5 months of the 1st dose and 73.4% receiving the 3rd dose 6 to 9 months after the 2nd dose. At baseline, median LDL-C was high (122.0 mg/dL) despite 77.9% of participants receiving lipid-lowering therapy (LLT); concomitant LLT use was reduced to 55.8% after initiating inclisiran. Median LDL-C reduction after the 1st and 2nd doses was 44.7% and 40.8%, respectively. In a subcohort with concomitant statin use, median LDL-C reduction from baseline was 55.7% and 56.0% after the 1st and 2nd dose, respectively, with 87.9% achieving LDL-C <55 mg/dL after the 2nd or 3rd dose. Absolute LDL-C reduction was consistent irrespective of concomitant statin use.
CONCLUSION: In a real-world setting in Austria, inclisiran demonstrated a favorable early therapeutic impact, including high adherence to the recommended dosing schedule and sustained LDL-C reductions.
PMID:42567787 | DOI:10.1016/j.jacl.2026.07.025